This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Johnson & Johnson
Drug Names(s): PER.C6-based seasonal influenza vaccine (FluCell)
Description: This trivalent split inactivated seasonal influenza vaccine is cell culture-based; specifically, it is based on Crucell's proprietary PER.C6 cell line technology.
Deal Structure: In December 2003, Sanofi pasteur, the vaccines business of sanofi-aventis, entered into a strategic and exclusive agreement with Crucell to further develop, manufacture and market cell-based novel influenza vaccine products based on Crucell's proprietary PER.C6 cell line technology. The agreement covers both pandemic and seasonal influenza vaccines. The agreement is known as the FluCell collaboration.
In July 2010, sanofi returned the commercial and development rights of FluCell to Crucell.
In October 2010, Johnson & Johnson and Crucell announced an agreement whereby Johnson & Johnson, through an affiliate, would acquire all outstanding equity of Crucell that it does not already own for approximately Euro 1.75 billion in a recommended cash tender offer. The offer was declared unconditional and completed in February 2011.
Pink Sheet FDA Performance Tracker: User Fee Goal Dates
Additional information available to subscribers only: